Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02881112 · ClinicalTrials.gov registry record · NA
A Registry Study to Evaluate Outcomes of PEMF Therapy in Subjects With Various Pain Etiologies
A NA study, sponsored by Regenesis Biomedical.
- Completed
- Registry status
- NA
- Development phase
- 180
- Enrollment target
NCT02881112 is a NA study that has completed, run by Regenesis Biomedical. The registered enrollment target is 180 participants.
The verdict
NCT02881112, a NA study, has completed, sponsored by Regenesis Biomedical.
- COMPLETED
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
Study Summary
The study is an open-label, non-controlled study of the safety and effectiveness of investigator determined Provant therapy in subjects with pain and/or edema from various pain etiologies. Information collected in the study will be entered into a registry database.
Interventions
- DEVICE Provant Therapy System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-12-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02881112
The ClinicalTrials.gov registry entry for NCT02881112 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regenesis Biomedical, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Provant Therapy System is the first listed.
NCT02881112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02881112 about?
NCT02881112 is a clinical study titled "A Registry Study to Evaluate Outcomes of PEMF Therapy in Subjects With Various Pain Etiologies". The study is an open-label, non-controlled study of the safety and effectiveness of investigator determined Provant therapy in subjects with pain and/or edema from various pain etiologies. Information collected in the study will be entered into a registry database.
What is the current status of trial NCT02881112?
This trial is currently completed. It is a NA study. The enrollment target is 180 participants. The study started on 2016-03. Estimated completion is 2017-12-14.
What interventions are being tested in trial NCT02881112?
The interventions under investigation include: Provant Therapy System (DEVICE).
Who is sponsoring clinical trial NCT02881112?
This trial is sponsored by Regenesis Biomedical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.